FATE

Over the past six months, Fate Therapeutics' stock has seen significant movement, with a 52-week low of $0.94 and a 52-week high of $3.23, and a share price of $2.52 as of September 17, 2026, representing a 152.00% increase from September 18, 2025. Key events include the Q1 2026 earnings release on May 13, 2026, the Annual General Meeting on June 12, 2026, and FDA IND Clearance for FT839 on July 10, 2026. The Q2 2026 earnings release was on August 13, 2026, followed by the initiation of the Phase 2 RECLAIM-LN Clinical Trial for FT819 on August 14, 2026. In August 2026, analysts from Piper Sandler, Wells Fargo, and Wedbush reiterated or maintained increased price targets, and Mizuho Securities issued a "Buy" rating. An update on the Phase 1 FT836 solid-tumor study occurred on August 31, 2026, and multiple clinical data presentations for FT819 and FT839 were announced for September 2026. Additionally, Johnson & Johnson disclosed a new position of approximately 3.38 million FATE shares.